Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226427 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
A Phase 1 study of Platinum-resistant Ovarian Cancer, sponsored by Stemline Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07226427 is a Phase 1 study of Platinum-resistant Ovarian Cancer that is actively recruiting participants, run by Stemline Therapeutics. The registered enrollment target is 100 participants, below the 180-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07226427, a Phase 1 study of Platinum-resistant Ovarian Cancer, is actively recruiting participants, sponsored by Stemline Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Conditions Studied
Interventions
- DRUG MEN2501
Study Locations (1)
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-11 |
| Est. Completion | 2028-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226427
The ClinicalTrials.gov registry entry for NCT07226427 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (44% lower). The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which MEN2501 is the first listed.
NCT07226427 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT07226427 about?
NCT07226427 is a clinical study titled "A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer". This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
What is the current status of trial NCT07226427?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-11. Estimated completion is 2028-06-02.
What conditions does trial NCT07226427 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer.
What interventions are being tested in trial NCT07226427?
The interventions under investigation include: MEN2501 (DRUG).
Who is sponsoring clinical trial NCT07226427?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226427 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RECRUITING · Phase 1
-
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.